Disc Medicine had its Relative Strength (RS) Rating upgraded from 79 to 85 Friday.
Risk Management In The Stock Market: How Much Money To Invest Now
This exclusive rating from Investor's Business Daily identifies share price movement with a 1 (worst) to 99 (best) score. The rating shows how a stock's price performance over the last 52 weeks compares to all the other stocks in our database.
History shows that the top-performing stocks typically have an RS Rating of over 80 in the early stages of their moves.
While the stock is not near a proper buy point right now, see if it manages to form and break out of a proper chart pattern.
The company showed 0% earnings growth last quarter, while sales growth came in at 0%. Look for the next report on or around May 19.
The company earns the No. 200 rank among its peers in the Medical-Biomed/Biotech industry group. GeneDx Holdings, ADMA Biologics and Catalyst Pharmaceuticals are among the top 5 highly rated stocks within the group.
This article was created automatically with Stats Perform's Wordsmith software using data and article templates supplied by Investor's Business Daily. An IBD journalist may have edited the article.
RELATED:
Biotech And Pharmaceutical Industry And Stock News
IBD Stock Rating Upgrades: Rising Relative Strength
Why Should You Use IBD's Relative Strength Rating?
How Relative Strength Line Can Help You Judge A Stock
Ready To Grow Your Investing Skills? Join An IBD Meetup Group!
